Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Cardiology
Volume 2014 (2014), Article ID 189895, 3 pages
http://dx.doi.org/10.1155/2014/189895
Case Report

Cheating the CHA2DS2-VASc Score: Thromboembolism in Apical Hypertrophic Cardiomyopathy

1Cardiology Department, Hairmyres Hospital, East Kilbride, Glasgow G75 8RG, Scotland
2Cardiology Department, Monklands Hospital, Airdrie, Scotland

Received 23 September 2014; Revised 11 November 2014; Accepted 12 November 2014; Published 20 November 2014

Academic Editor: Yoko Miyasaka

Copyright © 2014 Robin A. P. Weir et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Y. H. Lip, R. Nieuwlaat, R. Pisters, D. A. Lane, and H. J. G. M. Crijns, “Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation,” Chest, vol. 137, no. 2, pp. 263–272, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. “Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials,” Archives of Internal Medicine, vol. 154, no. 13, pp. 1449–1457, 1994. View at Publisher · View at Google Scholar · View at Scopus
  3. “Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study,” The Lancet, vol. 343, pp. 687–691, 1994.
  4. T.-F. Chao, C.-J. Liu, S.-J. Chen et al., “Atrial fibrillation and the risk of ischemic stroke: does it still matter in patients with a CHA2DS2-VASc score of 0 or 1?” Stroke, vol. 43, no. 10, pp. 2551–2555, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Chikamori, Y. L. Doi, M. Akizawa, Y. Yonezawa, T. Ozawa, and W. J. McKenna, “Comparison of clinical, morphological, and prognostic features in hypertrophic cardiomyopathy between Japanese and Western patients,” Clinical Cardiology, vol. 15, no. 11, pp. 833–837, 1992. View at Publisher · View at Google Scholar · View at Scopus
  6. C. R. Cannan, G. S. Reeder, K. R. Bailey, L. J. Melton III, and B. J. Gersh, “Natural history of hypertrophic cardiomyopathy: a population-based study, 1976 through 1990,” Circulation, vol. 92, no. 9, pp. 2488–2495, 1995. View at Publisher · View at Google Scholar · View at Scopus
  7. M. J. Eriksson, B. Sonnenberg, A. Woo et al., “Long-term outcome in patients with apical hypertrophic cardiomyopathy,” Journal of the American College of Cardiology, vol. 39, no. 4, pp. 638–645, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. M. E. Bertrand, P. Y. Tilmant, J. M. Lablanche, and F. A. Thieuleux, “Apical hypertrophic cardiomyopathy: clinical and metabolic studies,” European Heart Journal, vol. 4, pp. 127–133, 1983. View at Google Scholar · View at Scopus